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Abstract
Background: Tumor necrosis factor-α (TNF-α) antagonists, most of which are monoclonal antibodies, became a
widespread treatment for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory
bowel diseases, psoriasis, psoriatic arthritis, hidradenitis suppurativa and uveitis. Their use is based on the blockage
of TNF-α, which plays an important role in granulomas formation, development of phagosomes, activation and
differentiation of macrophages, immune response against viral pathogens. The multiple adverse effects of TNF-α
inhibition have been identified, including a two-to four-fold increased risk of active tuberculosis and other
granulomatous conditions and an increased occurrence of some other serious bacterial, fungal and certain viral
infections.
Case presentation: A 34-year-old male patient with disseminated varicella and pneumonitis was admitted to our
hospital. The diagnosis of varicella was established serologically by enzyme immunoassay (EIA) and by polymerase
chain reaction confirmation of the virus in vesicular fluid. The patient has been receiving adalimumab and
methotrexate for the last 3 years due to ankylosing spondylitis and was seropositive to varicella zoster virus prior to
the introduction of TNF-α antagonists. Acyclovir was administered for 10 days with the resolution of clinical illness
and radiological signs of pneumonitis.
Conclusion: Due to the use of biological agents, particularly TNF-α inhibitors, as a well-established therapy for
some autoimmune diseases, new potential adverse events can be expected in the future and we wanted to point
out one of them. To our knowledge this is the first case of recurrent disseminated varicella in a patient taking
TNF-α antagonists.
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Background
Tumor necrosis factor-α (TNF-α) antagonists, most of
which are monoclonal antibodies (infliximab, golimumab,
adalimumab), became a widespread treatment for auto-
immune diseases such as rheumatoid arthritis, ankylosing
spondylitis, inflammatory bowel diseases, psoriasis, psori-
atic arthritis, hidradenitis suppurativa and uveitis. Their
use is based on the blockage of TNF-α, which plays an im-
portant role in granulomas formation, development of
phagosomes, activation and differentiation of macro-
phages, immune response against viral pathogens [1–3].
Adalimumab is a recombinant human immunoglobulin
(Ig) G monoclonal antibody specific for human TNF-α
which causes modulation of the inflammatory response
activated by this cytokine.
However, multiple adverse effects of TNF-α inhibition
have been identified, including a two-to four-fold increased
risk of active tuberculosis and other granulomatous
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conditions and an increased occurrence of some other ser-
ious bacterial, fungal and certain viral infections [4–6].
Case presentation
We report a case of a 34-year-old patient with a medical
history of fever, malaise, cough, and generalized vesicular
rash that started 1 day before admission. 14 days prior to
disease onset, the patient’s son developed chickenpox.
The patient had a history of ankylosing spondylitis and
has been treated with adalimumab 40 mg subcutaneously
biweekly in addition to methotrexate10 mg per week for
the last 2 years. He had had chickenpox at the age of 5,
and positive IgG antibodies (titre 24; positive > 11) to
varicella-zoster virus (VZV) using EIA in 2014, prior to
the initiation of adalimumab treatment.
On admission to the hospital, physical examination re-
vealed a subfebrile (37.3 °C) patient with papular and
vesicular rash over the entire body (Fig. 1). Laboratory
test results showed: erythrocyte sedimentation rate
17 mm/1st hour, C-reactive protein 17,7mg/l, white
blood cell count 4,8 × 109/l with 56% neutrophils and 25%
lymphocytes in differential count, elevated fibrinogen
(3,1 g/l). Other standard parameters such as haemoglobin
concentration, platelet count, glucose concentration,
plasma ion levels, renal and liver functional tests, coagula-
tion tests and urinalysis were all normal. A chest radio-
graph showed diffuse bilateral nodular infiltrates (Fig. 2a).
Recurrent varicella infection was suspected and intravenous
acyclovir was administered (10mg/kg every 8 h). A Tzanck
smear revealed multinucleated giant cells and VZV deoxy-
ribonucleic acid (DNA) was detected in vesicular fluid by
polymerase chain reaction. Serological testing for VZV
using EIA was performed on the third day of illness and
IgM (titre 15; positive > 11), IgG (titre 36; positive > 11) and
IgA (titre 12; positive > 11) antibodies to VZV were de-
tected. Based on the clinical and laboratory findings, the
diagnosis of recurrent varicella with pneumonia was estab-
lished. The patient was treated with intravenous acyclovir
(750mg every 8 h) for 7 days, followed by oral acyclovir
(800mg five times daily) for 3 more days. He remained
febrile for 3 days with rapid resolution of the rash and
radiological resolution of pulmonary infiltrates (Fig. 2b).
Discussion and conclusions
Patients receiving TNF-α antagonists therapy remain at
a selectively increased risk for more severe primary vari-
cella infections compared with the general population,
with the estimated incidence rate of hospitalization due
to chickenpox of 26 cases per 100,000 (95% CI 10–69)
compared with the expected rate of 1.9 (95% CI 1.8–2.0)
Fig. 1 Papular and vesicular rash on the neck and trunk
Fig. 2 a Chest radiograph on the day of admission revealed diffuse nodular infiltrates. b Radiological resolution of pulmonary infiltrates after 10
days of acyclovir therapy
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in the general population [7]. Contradictory results have
been published reporting the association between
TNF-α therapy and herpes zoster.
Several large population-based studies have been con-
ducted, with those performed in the United States not
finding an increased risk with TNF-α inhibitors, contrary
to those in Europe generally showing an increased risk
[4, 8, 9]. There were multiple reports of severe and dis-
seminated herpes zoster and primary varicella associated
with TNF-α therapy (infliximab and adalimumab) [1,
10–15]. In contrast, recurrent varicella infections during
TNF-α therapy were rarely reported, with only one case
featuring few clinical symptoms (no dissemination and
resolution of skin lesions without antiviral treatment) in
the course of etanercept administration [16]. VZV causes
two clinically distinct diseases - primary infection result-
ing in varicella and herpes zoster resulting from the re-
activation of latent VZV that gained access to sensory
ganglia during varicella [17]. It is traditionally considered
that VZV infection provides lifelong immunity but re-
current infection (also referred to as reinfection or sec-
ond varicella infection) with VZV occur more commonly
than previously thought [18, 19]. In an active surveil-
lance initiative in California, the percentage of patients
diagnosed with varicella who reported previous varicella
infections ranged from 4.5 to 13.3% [18]. VZV recurrent
infection can occur even in immunocompetent patients,
and our patient was predisposed to infection by his
rheumatologic disease and immunosuppressive therapy.
Patients with a history of underlying malignancy, steroid
use or immunosuppressive therapy, HIV infection, or
solid organ transplantation are susceptible for dissemi-
nated varicella due to impaired cellular immunity. Clin-
ical manifestations in the immunosuppressed host can
include atypical and severe manifestations such as devel-
opment of crops of vesicles over weeks, large and haem-
orrhagic skin lesions, pneumonia, or widespread disease
with disseminated intravascular coagulation [17, 20].
The antiviral therapy is recommended for immunocom-
promised hosts who present with varicella because they
are at risk for developing disseminated varicella, as our
patient has been, and can also experience more frequent
severe morbidity and higher mortality rates compared
with immunocompetent hosts [20, 21]. Early clinical rec-
ognition of VZV infection in high risk patients, such are
all immunocompromised patients, as well as laboratory
detection and confirmation of VZV require early aggres-
sive antiviral treatment leading to favourable clinical
outcome [7, 17, 20].
Due to the use of biological agents, particularly TNF-α
inhibitors, as a well-established therapy for some auto-
immune diseases, new potential adverse events can be
expected in the future and we wanted to point out
one of them. To the best of our knowledge, this is
the first case of confirmed recurrent varicella with
disseminated disease and pneumonia in a patient
receiving adalimumab since this drug has been ap-
proved for use in 2002 in the United States and 2003
in the European Union [22, 23].
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